This contract expires in 142 days (Oct 31, 2026).
NOVARTIS PHARMACEUTICALS CORPORATION - PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML)
Key Details
Description
PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML)
Context & Analysis
On Oct 28, 2025, Department of Veterans Affairs obligated $299,062.26 to NOVARTIS PHARMACEUTICALS CORPORATION for pluvicto (lutetium lu 177 vipivotide tetra 27mci/ml). The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in EAST HANOVER, NJ. The contract is scheduled through Oct 31, 2026 — approximately 5 months remaining. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.